Publicaciones en colaboración con investigadores/as de Hospital del Mar (16)

2023

  1. Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry

    Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159

2020

  1. Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients

    Cancer Treatment Reviews, Vol. 83

2018

  1. Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial

    JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308

2016

  1. Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile

    Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428

2015

  1. Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design

    Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315

2014

  1. Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors

    Critical Reviews in Oncology/Hematology, Vol. 89, Núm. 1, pp. 62-72

2013

  1. Finding the right dose of fulvestrant in breast cancer

    Cancer Treatment Reviews, Vol. 39, Núm. 2, pp. 136-141

  2. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study

    Journal of Clinical Oncology

2010

  1. Current controversies in the management of breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286

  2. Current perspectives of treatment of ductal carcinoma in situ

    Cancer Treatment Reviews, Vol. 36, Núm. 7, pp. 507-517

  3. Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))

    Clinical and Translational Oncology

  4. Supportive care for patients with early breast cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42

2008

  1. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer

    Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709

2007

  1. Advanced breast cancer: Chemotherapy phase III trials that change a standard

    Anti-Cancer Drugs

  2. Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials

    Cancer Treatment Reviews, Vol. 33, Núm. 5, pp. 474-483

  3. The use of taxanes in the neoadjuvant treatment of breast cancer: A review of randomized phase II/III trials

    Clinical Breast Cancer, Vol. 7, Núm. 10, pp. 764-774